Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.70 |
| ▸ | RARB | P10826 | 9/20 | 0.70 |
| ▸ | RARG | P13631 | 8/20 | 0.70 |
| ▸ | RXRB | P28702 | 8/20 | 0.70 |
| ▸ | RXRG | P48443 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.67 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.62 |
| ▸ | RARA | P10276 | 7/20 | 0.61 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788640 | 0.91 | CYP3A4 (0.70) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL8026112 | 0.90 | RARB (0.58) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL7899482 | 0.90 | RXRA (0.61) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL9319204 | 0.88 | CYP3A4 (0.67) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL8733241 | 0.87 | RARB (0.83) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL7421190 | 0.85 | RXRA (0.72) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL7421758 | 0.85 | RXRA (0.72) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL9187540 | 0.85 | CYP3A4 (0.76) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL9187032 | 0.84 | CYP3A4 (0.74) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL20398871 | 0.84 | RARB (0.57) | RXRARARBRARGRXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0260162-B1 | BICYCLIC AROMATIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA Groupement d'Intérêt Economique dit: (FR) | 1990-11-14 | — | — | EP | claimed |
| US-6476017-B2 | (DIBENZO(B,E)(1,4)-DIAZEPINE-11-YL)BENZOIC ACID DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-0906907-B1 | COMPOUNDS POTENTIATING RETINOID | INST MED MOLECULAR DESIGN INC (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-20010039272-A1 | Compounds activating pharmacological effect of retinoids | KEMPHYS LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6121256-A | 4-(2,3-(2,5-DIMETHYL-2,5-HEXANO)DIBENZO(B,F)(1,4)THIAZEPINE-11 -YL)BENZOIC ACID OR SALT | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-5929069-A | CARBOXYPHENYL-SUBSTITUTED DIBENZO(B,F)(1,4)DIAZEPINE DERIVATIVES; TREATMENT OF VITAMIN A DEFICIENCY DISEASES, SKIN DISORDERS, LEUKEMIA | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 1999-07-27 | — | — | US | disclosed |
| EP-0906907-A1 | COMPOUNDS POTENTIATING RETINOID | Institute of Medicinal Molecular Design, Inc. (JP) | 1999-04-07 | — | — | EP | disclosed |
| US-5837725-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
| US-5824484-A | GENTIC ENGINEERING AND SCREENING A SUBSTANCE FOR RETINOID X RECEPTORS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1998-10-20 | — | — | US | disclosed |
| US-5552271-A | SCREENING FOR SUBSTANCES WHICH INDUCE FORMATION OF RETINOID XRECEPTOR HOMODIMERS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5466861-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0671005-A1 | RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012880-A2 | RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039272-A1 | Compounds activating pharmacological effect of retinoids | RXRA, RXRG, RXRB | RXRA 1/4885RARB 5/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.